Sign Out
Increased bleeding time has been seen when Trademark is given in conjunction with oral anticoagulants or other drugs affecting coagulation (e.g. acetylsalicylic acid or NSAIDs). This may result from a possible additive effect on bleeding time, but haemorrhagic complications have not been documented (see Precautions).
Acetylsalicylic acid: Patients should be informed about potentially increased bleeding time.
Anti-coagulants: Omacor has been given in conjunction with warfarin without haemorrhagic complications. However, the prothrombin time/International normalized ratio (PT/INR) must be checked when Omacor is combined with drug affecting PT/INR or when treatment with Omacor is stopped.
Continue with Google